#1 Clinical Trials Search in Europe

Ecubectedin

This article discusses the ongoing clinical trials of Ecubectedin (PM14), a promising drug being studied in combination with irinotecan for the treatment of various advanced solid tumors. The trials aim to determine the optimal dosage, evaluate safety and effectiveness, and explore potential biomarkers for treatment response. This research could potentially offer new hope for patients with difficult-to-treat cancers who have exhausted standard treatment options.

Table of Contents

What is ECUBECTEDIN?

ECUBECTEDIN, also known as PM14, is a new drug being studied for the treatment of advanced solid tumors[1]. It is a chemical substance that is being developed as a potential cancer treatment. ECUBECTEDIN is currently undergoing clinical trials to evaluate its effectiveness and safety when used in combination with another drug called irinotecan.

Medical Conditions Treated

ECUBECTEDIN is being investigated for the treatment of various advanced solid tumors[1]. These include:

  • Gastrointestinal cancers: Such as esophageal carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, biliary tract carcinoma, liver cancer, and certain types of neuroendocrine tumors
  • Lung cancers: Including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
  • Sarcomas: Such as liposarcoma, leiomyosarcoma, synovial sarcoma, and Ewing’s sarcoma
  • Gynecological cancers: Including ovarian cancer, endometrial cancer, and cervical cancer
  • Breast cancer: Both ductal and lobular carcinomas
  • Genitourinary cancers: Such as bladder cancer, kidney cancer, and prostate cancer
  • Other cancers: Including mesothelioma, extrapulmonary small cell carcinoma, and adrenocortical carcinoma

These are all considered advanced solid tumors, meaning they are cancers that have spread or are in later stages of development[1].

How ECUBECTEDIN is Administered

ECUBECTEDIN is administered as an intravenous perfusion, which means it is given directly into the bloodstream through a vein[1]. The drug comes in the form of a powder that is made into a solution for infusion. The maximum dose being studied is 4.5 mg/m² (milligrams per square meter of body surface area).

Clinical Trial Objectives

The ongoing clinical trial for ECUBECTEDIN has several objectives[1]:

  1. To determine the safe and effective dose of ECUBECTEDIN when used with irinotecan
  2. To evaluate how well the combination of ECUBECTEDIN and irinotecan works in treating advanced solid tumors
  3. To assess the safety and side effects of this drug combination
  4. To study how the drugs interact in the body (pharmacokinetics)
  5. To investigate genetic factors that might affect how patients respond to the treatment

Eligibility Criteria

To participate in the ECUBECTEDIN clinical trial, patients must meet certain criteria[1]:

  • Have an advanced solid tumor that has not responded to standard treatments
  • Be in relatively good overall health (ECOG performance status ≤ 1)
  • Have adequate bone marrow, kidney, and liver function
  • Not have certain heart conditions or active infections
  • Not be pregnant or breastfeeding

There are also specific criteria regarding prior treatments and the timing of entering the study.

Safety and Side Effects

As with all cancer treatments, ECUBECTEDIN may cause side effects. The clinical trial is closely monitoring patients for any adverse events[1]. Some potential side effects being watched for include:

  • Decreased blood cell counts
  • Liver function changes
  • Kidney function changes
  • Muscle-related issues (monitored through CPK levels)

The study team will grade any side effects according to standardized criteria and may adjust or stop treatment if necessary.

Future Research

The clinical trial for ECUBECTEDIN includes plans for further research[1]:

  • Pharmacogenetics: Studying how genetic factors affect how patients respond to the drug
  • Pharmacogenomics: Analyzing tumor and blood samples to identify potential biomarkers that might predict who will respond best to the treatment

These studies aim to personalize treatment and improve outcomes for future patients.

Aspect Details
Drug Name Ecubectedin (PM14)
Trial Phase Phase I/II
Combination Ecubectedin with Irinotecan
Target Population Patients with selected advanced solid tumors
Primary Objectives Determine maximum tolerated dose, recommended dose, and evaluate antitumor activity
Secondary Objectives Evaluate safety, pharmacokinetics, pharmacogenetics, and explore biomarkers
Key Eligibility Criteria Advanced solid tumors, ECOG status ≤1, adequate organ function
Primary Endpoints Determination of MTD/RD, Overall Response Rate
Secondary Endpoints Safety assessment, pharmacokinetic analysis, pharmacogenetic evaluation, efficacy measures

FAQ

  • What is Ecubectedin (PM14)? Ecubectedin, also known as PM14, is an investigational drug being studied for the treatment of advanced solid tumors. It is being tested in combination with another drug called irinotecan in clinical trials.
  • What types of cancers are being studied in these trials? The trials are focusing on various advanced solid tumors, including gastrointestinal cancers, lung cancers, sarcomas, gynecological cancers, breast cancer, genitourinary tract tumors, and others such as malignant pleural mesothelioma and adrenocortical carcinoma.
  • What are the main goals of these clinical trials? The main goals are to determine the best dose of Ecubectedin when combined with irinotecan, evaluate its safety and effectiveness, and study how the drug behaves in the body. The trials also aim to identify potential biomarkers that might predict how well a patient will respond to the treatment.
  • Who can participate in these trials? Participants must have advanced solid tumors that have not responded to standard treatments. They need to meet specific health criteria, including adequate organ function and recovery from previous treatments. Patients with certain medical conditions or recent use of specific medications may not be eligible.
  • How will the effectiveness of the treatment be measured? The effectiveness will be primarily measured by the overall response rate, which is the percentage of patients whose tumors shrink or disappear after treatment. Other measures include how long the treatment keeps the cancer from growing and how long any improvements last.

Ongoing Clinical Trials on Ecubectedin

  • Study of PM14 Alone and with Radiotherapy for Patients with Advanced Soft Tissue Sarcomas and Other Solid Tumors

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of PM14 and Irinotecan for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Ecubectedin (PM14): An investigational drug being studied for the treatment of advanced solid tumors, often in combination with irinotecan.
  • Solid Tumors: Abnormal masses of tissue that don't contain cysts or liquid areas. They may be benign (not cancer) or malignant (cancer).
  • Maximum Tolerated Dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Recommended Dose (RD): The dose of a drug that is considered to be the most effective and safe for use in patients.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacogenetics (PGt): The study of how a person's genes affect their response to drugs.
  • Biomarkers: Measurable indicators in the body that can predict how well a patient might respond to a treatment.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Duration of Response (DoR): The length of time that a tumor continues to respond to treatment without the cancer growing or spreading.

References

  1. http://clinicaltrials.eu/trial/study-of-pm14-and-irinotecan-for-patients-with-advanced-solid-tumors/